Table 1.
Baseline characteristics of study population.
| Clinical Parameters | All Patients N = 140 |
Normal Iron N = 73 |
ID N = 67 |
ID Type I N = 45 |
ID Type II N = 22 |
p Value ID vs. Normal Iron |
p Value ID I vs. ID II vs. Normal Iron |
|---|---|---|---|---|---|---|---|
| Age, y, mean ± SD | 69 ± 13 | 67 ± 12 | 70 ± 14 | 66 ± 14 | 77 ± 12 * | n.s. | <0.01 |
| Body mass index, kg/m², mean ± SD | 27.7 ± 4.6 | 28.3 ± 4.8 | 27.1 ± 4.2 | 26.0 ± 3.8 | 27.5 ± 4.3 | n.s. | n.s. |
| Systolic RR, mmHg, mean ± SD | 136 ± 28 | 137 ± 33 | 135 ± 21 | 146 ± 18 | 136 ± 22 | n.s. | n.s. |
| Diastolic RR, mmHg, mean ± SD | 79 ± 14 | 81 ± 13 | 77 ± 14 | 84 ± 10 | 75 ± 16 | n.s. | n.s. |
| Female sex N, % | 55 (39) | 17 (23) | 38 (57) | 26 (58) | 12 (55) | <0.001 | <0.001 |
| Self-reported appetite | 6.5 ± 2.2 | 6.7 ± 2.1 | 6.3 ±2.3 | 6.8 ± 2.1 | 5.4 ± 2.4 * | n.s. | 0.05 |
| Stroke severity National Institute of Health Stroke Scale (NIHSS) | |||||||
| Mean score ± SD | 4.7 ± 3.4 | 4.8 ± 3.6 | 4.6 ± 3.1 | 4.1 ± 2.7 | 5.6 ± 3.6 | n.s | n.s. |
| 0–4, N (%) | 83 (59) | 42 (57) | 41 (62) | 32 (71) | 9 (41) | n.s. | n.s. |
| Trial of ORG 10172 in Acute Stroke Treatment | |||||||
| Cardioembolic, N (%) | 44 (31) | 20 (27) | 24 (36) | 12 (27) | 12 (55) * | n.s. | <0.05 |
| Large-artery atherosclerosis, N (%) | 49 (35) | 26 (36) | 23 (35) | 16 (36) | 7 (32) | n.s. | n.s. |
| Small-vessel occlusion, N (%) | 25 (18) | 14 (19) | 11 (16) | 9 (20) | 2 (9) | n.s. | n.s. |
| Stroke of undetermined etiology | 22 (16) | 13 (18) | 9 (13) | 8 (17) | 1 (4) | n.s. | n.s. |
| Physical status | |||||||
| Modified Rankin Scale (mRS) | |||||||
| Mean score ± SD | 2.4 ± 1.5 | 2.4 ± 1.6 | 2.4 ± 1.6 | 2.1 ± 1.3 | 2.9 ± 1.6 | n.s | n.s. |
| 0–1, N (%) | 58 (41) | 32 (44) | 26 (39) | 19 (42) | 7 (32) | n.s. | n.s. |
| Low Handgrip strength, N (%) | 61 (44) | 28 (38) | 33 (49) | 19 (42) | 14 (64) | n.s. | n.s. |
| Comorbidities | |||||||
| Diabetes mellitus, N (%) | 40 (29) | 19 (26) | 21 (38) | 13 (36) | 7 (33) | n.s. | n.s. |
| Arterial hypertension, N (%) | 96 (69) | 49 (67) | 47 (70) | 31 (69) | 16 (76) | n.s. | n.s. |
| Dyslipidemia, N (%) | 45 (32) | 22 (30) | 23 (34) | 17 (38) | 6 (27) | n.s. | n.s. |
| Anemia, N (%) | 25 (19) | 7 (10) | 18 (27) | 9 (20) | 9 (41) | <0.01 | <0.01 |
| Cardiovascular disease, N (%) | 56 (40) | 29 (40) | 29 (43) | 15 (33) | 5 (23) | n.s. | n.s. |
| Biochemistry | |||||||
| Hemoglobin, mg/dL, mean ± SD | 14.0 ± 1.9 | 14.6 ± 1.7 | 13.3 ± 1.8 | 13.4 ± 1.8 | 13.1 ± 1.9 | n.s. | 0.0001 |
| White blood cells count | 8.3 ± 2.5 | 8.1 ± 1.9 | 8.7 ± 3.1 | 8.1 ± 2.3 | 10.1 ± 4.2 ** | n.s. | <0.01 |
| Creatinine, mg/dL, mean ± SD | 1.0 ± 0.4 | 1.0 ± 0.4 | 1.0 ± 0.4 | 1.0 ± 0.4 | 0.9 ± 1.9 | n.s. | n.s. |
| Cholesterol, mg/dL, mean ± SD | 186 ± 43 | 189 ± 37 | 182 ± 49 | 190 ± 50 | 166 ± 43 * | n.s. | n.s. |
| High density lipoprotein, mg/dL, mean ± SD | 49 ± 15 | 46 ± 12 | 51 ± 16 | 54 ± 17 * | 46 ± 12 | <0.05 | <0.05 |
| Low density lipoprotein, mg/dL, mean ± SD | 110 ± 38 | 115 ± 34 | 104 ± 41 | 109 ± 39 | 93 ± 45 | n.s. | n.s. |
| Hemoglobin A1c, %, median [IQR] | 5.9 [5.4–6.5] | 5.8 [5.4–6.5] | 5.9 [5.5–6.5] | 5.8 [5.5–6.7] | 5.6 [5.6–6.6] | n.s | n.s. |
| C-reactive protein, mg/L, median [IQR] | 4.8 [1.7–11.8] | 4.1 [1.7–12] | 6.6 [1.7–10.35] | 4.1 [1.7–7] | 16.7 [7.2–26.2] * | n.s | <0.01 |
| Systemic inflammation, N (%) | 63 (45) | 30 (41) | 33 (49) | 16 (35) | 17 (77) * | n.s. | n.s. |
| Medication | |||||||
| Antiplatelet drugs, N (%) | 120 (86) | 61 (84) | 59 (88) | 41 (91) | 18 (82) | n.s. | n.s. |
| Anticoagulants, N (%) | 29 (21) | 16 (22) | 13 (19) | 6 (13) | 7 (32) | n.s. | n.s. |
| Proton pump inhibitors, N (%) | 34 (24) | 16 (22) | 18 (27) | 13 (29) | 5 (23) | n.s. | n.s. |
| β-blocker, N (%) | 57 (41) | 28 (38) | 29 (43) | 17 (38) | 12 (55) | n.s. | n.s. |
| ACE-inhibitors, N (%) | 65 (46) | 39 (53) | 26 (39) | 15 (45) | 11 (50) | n.s. | n.s. |
| Ca2+-channel antagonists, N (%) | 14 (10) | 7 (10) | 7 (19) | 5 (11) | 2 (9) | n.s. | n.s. |
| Angiotensin II receptor blockers, N (%) | 4 (3) | 2 (3) | 2 (3) | 1 (2) | 1 (5) | n.s. | n.s. |
| Diuretics, N (%) | 29 (21) | 12 (16) | 17 (25) | 10 (22) | 7 (32) | n.s. | n.s. |
| Statins, N (%) | 100 (71) | 53 (73) | 47 (70) | 37 (82) | 10 (45) | n.s. | n.s. |
ACE, angiotensin converting enzyme; IQR, interquartile range; LDL, high-density lipoprotein; SD, standard deviation. * p < 0.05 vs. Normal Iron; ** p < 0.01 vs. Normal Iron. n.s., non-significant.